Treatment of Bacterial and Protozoal Vaginal Infections

Colpofilin is fundamentally used as a targeted anti-infective to address the primary causes of symptomatic vaginitis, specifically the overgrowth associated with Bacterial Vaginosis (BV) and the infection caused by the protozoan Trichomonas vaginalis. The active ingredient is commonly applied intravaginally for these conditions. The therapeutic focus is the clearance of the specific pathogens, which generally supports a return to the local microbial balance and clearing the underlying condition.

---

Relief from Acute Discomfort and Disturbing Symptoms

This medicine is commonly used to help manage the symptomatic manifestations of these infections, including addressing abnormal vaginal discharge, the characteristic unpleasant vaginal odor, and local discomforts like itching, burning, and irritation. This focused symptomatic relief may contribute to supporting day-to-day comfort during symptomatic periods. The medicine is relevant in clinical settings that involve acute or unstable symptom patterns and sometimes recurrent episodes.

“It may provide supportive relief when symptoms become more noticeable and interfere with routine activities.”

---

Key Therapeutic Focus

The primary uses for this medication include managing Bacterial Vaginosis, helping with Trichomoniasis, and addressing the local microbial imbalances that may cause these specific symptomatic conditions.

Quick Fact: Relief for Localized Discomfort
The treatment is commonly used to help address symptom clusters that create noticeable functional strain, and may provide supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH StatPearls overview

Colpofilin (Metronidazole Vaginal) eligibility is strictly defined by regulatory documents, establishing clear limitations on who may use the medicine.

Absolute Contraindications

The medication is contraindicated and must not be used by patients with a prior history of hypersensitivity to Metronidazole or other nitroimidazole derivatives. Use is also strictly prohibited for individuals who have taken Disulfiram concurrently or within the last two weeks, or for anyone who consumes alcohol during the course of therapy and for a specified time period afterward, due to the risk of severe adverse reactions.

Population Restrictions and Conditional Use

The medicine is indicated for use in females aged 12 years and older. Safety and effectiveness have not been established for females under 12 years of age.

Use requires caution and close medical oversight for patients with severe hepatic disease or a history of Central Nervous System (CNS) disorders. For patients taking Warfarin or other anticoagulants, use is conditional due to potential interaction.

During pregnancy, use is determined by a healthcare provider. During lactation, official guidance often recommends the temporary discontinuation of breastfeeding during treatment and for a period after the final dose.

Interaction Map: Interactions with other medicines and products — official regulatory information for Colpofilin

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Coumarin Anticoagulants
Specific interacting medicines (if explicitly listed):	Disulfiram, Warfarin, Cimetidine, Lithium
Mechanistic basis of interactions (only if stated in label):	Inhibition of CYP450 2C9 (Warfarin interaction); Decreased Plasma Clearance (Cimetidine interaction)
Timing-based interaction rules (if applicable):	Must be separated by at least two weeks (Disulfiram); Must be avoided for at least three days after treatment (Alcohol/Ethanol)
Population-specific interaction notes (if applicable):	Severe Hepatic Disease (results in reduced clearance and accumulation of metronidazole)
Interaction-related restrictions:	Prohibition of co-administration (Disulfiram); Prohibition of consumption (Alcohol/Ethanol and Propylene Glycol-containing products)

---

Interaction Classifications (High-Level)

Classification Type	Official Regulatory Documentation
Interaction severity classification (as defined in official documents):	Contraindicated Combination (Disulfiram)
Regulatory basis (EMA / FDA / etc.):	Information is based on government regulatory documents, including FDA Prescribing Information and NIH reviews.
Interaction-context constraints (as defined in official documents):	Drug-Drug Interaction; Drug-Substance Interaction; Drug-Laboratory Test Interference

---

Resulting interaction structure

Official interaction statements:

• Co-administration with Disulfiram is formally prohibited (contraindicated), including use within the last two weeks of Disulfiram administration, due to the documented risk of psychotic reactions.
• The active ingredient, Metronidazole, has a documented pharmacokinetic interaction with Warfarin and other Coumarin Anticoagulants, which potentiates the anticoagulant effect and prolongs prothrombin time. This is classified as Inhibition of CYP450 2C9.
• Co-administration with Cimetidine is documented to decrease the plasma clearance and prolong the serum half-life of metronidazole.
• Lithium is associated with the potential for elevation of serum lithium levels and the risk of toxicity.
• Consumption of Alcohol (Ethanol or Propylene Glycol-containing products) is restricted during therapy and for at least three days following the final dose, due to the potential for a disulfiram-like reaction.
• Patients with severe hepatic disease are officially noted as a population where the active ingredient metabolizes slowly, resulting in accumulation.
• The active ingredient may interfere with certain serum chemistry value determinations (e.g., AST, ALT, LDH).

Connection to the overall interaction profile (3 sentences): The official interaction structure for this product is fundamentally defined by mandatory restrictions against Disulfiram and Alcohol alongside documented pharmacokinetic interactions that alter the clearance of both the active ingredient and specific co-administered medications, such as Warfarin and Lithium. These regulatory statements establish constraints for co-administration or timing separation, regardless of the active ingredient's route of administration. The profile further includes specific clearance considerations for patients with severe hepatic disease, defining a population-specific interaction context.

Reductive Activation: Exploiting Anaerobic Metabolism

The mechanism of action for Metronidazole (the active ingredient) is defined by a specific biochemical process that exploits the unique metabolic environment of its microbial targets. The process critically relies on electron-transport proteins like ferredoxin within susceptible anaerobic bacteria and protozoa. These proteins donate low-potential electrons to the drug's nitro group, chemically reducing it to a highly reactive nitro-radical intermediate. This activation is dependent on the low-oxygen (anaerobic) conditions generated by the pathogen's metabolism, confining the drug's activity to the target cell.

Irreversible DNA Damage and Cytotoxicity

This domain addresses the destructive consequences of the activated radical. The short-lived, cytotoxic radical intermediate rapidly attacks and binds to the microorganism's essential DNA and other critical macromolecules. This interaction causes DNA strand breakage and collapse of the helical structure, which irreversibly halts the cell's ability to replicate or repair itself. The resulting physiological consequence is bactericidal and protozoacidal activity, which involves the destruction and clearance of the susceptible pathogenic population.

The administration of Colpofilin is defined as the intravaginal insertion of one 500 mg ovule once daily. This regimen, which represents the standard adult dose, is typically administered in the evening or at bedtime for optimal local effect. The precise duration of use is defined by the condition being addressed, lasting 7 consecutive days for nonspecific vaginitis and 10 consecutive days for trichomoniasis.

Procedural conditions for use include the requirement that the ovule must be inserted deeply into the vagina. For the treatment of trichomoniasis, simultaneous treatment of the sexual partner is considered an essential component of the protocol. Furthermore, administration should continue uninterrupted throughout the entire prescribed course, even if the patient's menstrual period begins.

A crucial administration constraint is the limitation on total exposure. A single course of treatment shall not exceed 10 days, and the total number of treatment courses is restricted to 2 to 3 per year. Population-specific rules also apply: the medicine is for adult patients only, and a dose reduction is indicated for individuals with severe hepatic impairment.

Research evidence / Overview of studies for Colpofilin

---

Evidence for Use in Bacterial Vaginosis (BV)

The research for the active component in Colpofilin primarily involves short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that explore its use in managing Bacterial Vaginosis (BV). These studies examined the medicine's component when administered locally via the vaginal route, often comparing the outcomes to other treatment methods or placebo. Researchers monitored specific physiological changes and patient-reported outcomes, such as the resolution of clinical signs and symptom change. Studies reported measured patterns related to short-term changes in diagnostic criteria and shifts in measured microbial scores. This research provides insight into short-term changes and helps contextualize how patients reported their experience during periods of heightened symptom activity.

Evidence for Use in Trichomoniasis

The active component of Colpofilin was studied for the measured clearance of Trichomonas vaginalis. The research explored its use primarily through Randomized Controlled Trials and specific Pilot Studies that focused on microbiological outcomes. These studies examined endpoints such as the confirmed absence of the pathogen. Findings indicate that the majority of the foundational research for the measured clearance of T. vaginalis focuses on systemic (oral) administration, which is considered a standard method. Studies that specifically evaluated localized vaginal delivery of the medicine's component reported different measured clearance rates compared to those described for the oral route.

---

Long-Term Evidence and Follow-up for Recurrence

The typical duration of observation for assessing initial measured study endpoints for BV is usually around four weeks post-treatment. Beyond this initial period, studies monitored patterns related to how often the infection returned. The available long-term data for both indications are primarily limited to tracking recurrence. Research highlights that the initial time points studied reported measurements related to measured study endpoints in the observed populations; however, long-term outcomes are not fully established. The follow-up durations used in the research were limited for drawing definitive conclusions about long-term maintenance.

What is Still Uncertain in the Research Record

The current body of research provides context but not individual predictions, and certain areas remain topics of ongoing research and uncertainty. For Trichomoniasis, the evidence supporting localized administration is limited compared to the robust findings for systemic delivery. Additionally, there is limited information for long-term outcomes related to the sustained tracking of recurrence for Bacterial Vaginosis.

Key Studies & References

1. Antibiotics for treating bacterial vaginosis in pregnancy (Cochrane Review)
2. Trichomoniasis - StatPearls (NIH Bookshelf)

Common questions about Colpofilin (FAQ)

---

Q: How quickly does Colpofilin typically begin to show its intended effect?

Official information indicates that the active ingredient, metronidazole, starts working (is absorbed) shortly after application. However, noticeable improvement in symptoms usually takes a couple of days. Official instructions emphasize the importance of completing the entire course of treatment to support the best possible outcome.

Q: What age groups were included in the main clinical trials for Colpofilin?

Clinical trials for formulations containing the active ingredient, metronidazole vaginal ovules or gel, commonly included individuals from postmenarcheal adolescence (ages 12 and up). This means research subjects generally included both adolescents between the ages of 12 and 18, as well as adult women.

Q: How long after stopping Colpofilin do its effects usually last?

The medicine is designed to treat the targeted infection completely during the prescribed course of therapy. Official documentation focuses on monitoring for potential recurrence of the infection after treatment, rather than the duration of the drug's effects. Recurrence is a documented risk in the conditions treated, especially if treatment is stopped early or if re-infection occurs.

Q: Can Colpofilin be used during pregnancy or while breastfeeding?

Regulatory guidance for the active ingredient suggests that its use while pregnant is possible and is determined by a healthcare provider. When breastfeeding, only small amounts of the medicine pass into milk, and it is not likely to cause side effects in the infant when the medication is used vaginally. Official sources advise caution regarding infant contact with the application area.

Q: Does Colpofilin affect fertility or reproductive function?

Based on regulatory documentation and supporting studies, there is no clear evidence to suggest that the active ingredient, metronidazole, reduces fertility in either men or women. This information reflects the current understanding available in official product documentation.

Q: Is it normal to feel a mild sensation when using Colpofilin?

The official safety profile for the active ingredient lists localized effects such as itching, burning, or irritation of the genital area as common adverse reactions. Localized effects such as irritation are officially documented as common. Any severe or worsening reaction is a reason to seek consultation with a healthcare provider.

Q: What kind of studies have been done on the effects of Colpofilin?

The effects of the active ingredient, Metronidazole, have been primarily examined in controlled clinical trials. These studies include Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews, which focus on measured outcomes such as microbial clearance and symptom resolution in the observed populations.

Q: Can Colpofilin be used by women of all ages?

The medicine is indicated for use only in females aged 12 years and older. Official regulatory bodies state that the safety and effectiveness of this product have not been established for females under 12 years of age.

Q: Does Colpofilin contain any common allergens or ingredients?

Colpofilin contains the active ingredient metronidazole and a solid base for the ovule formulation. Specific common inactive ingredients (excipients) in similar metronidazole formulations can include substances such as propylene glycol, parabens, and polyethylene glycol. The full ingredient list should be reviewed to address any sensitivities.

Q: Can Colpofilin be used at the same time as other topical products?

Official regulatory guidance generally advises that patients should refrain from using any other intravaginal product during the course of treatment. Official guidance advises against this, as the use of other products may interfere with the ovule's action.

Q: Is there a waiting period required after using Colpofilin before intimacy?

Official safety guidance recommends abstaining from sexual intercourse during the full treatment period. This restriction is established in regulatory safety guidance.

Q: What happens if I miss a scheduled application of Colpofilin?

If a dose is missed, patient instructions advise using it as soon as possible upon remembering. However, if it is near the time for the next scheduled dose, official instructions state the missed dose should be skipped rather than taking two doses at once.

Q: Are there different strengths or versions of Colpofilin available?

The Colpofilin ovule formulation is a 500 mg ovule designed for vaginal use. The active ingredient itself (metronidazole) is available in different strengths and other forms, such as oral tablets or topical gels, for various indications and routes of administration.

Q: Can Colpofilin be used during the menstrual period?

Official regulatory instructions explicitly state that the course of treatment should continue uninterrupted, even if the patient's menstrual period begins during the treatment time. However, it is noted that some clinical trials have excluded individuals who were already menstruating at the start of the study.

Q: Are there any known issues with Colpofilin and certain medical devices?

Official product information advises patients to refrain from using any intravaginal device during treatment. This restriction includes common devices such as tampons, diaphragms, or condoms, due to the potential for interference with the local effect of the medicine.

Q: What is the consistency or texture of the product (gel, cream, tablet)?

Colpofilin is supplied as Vaginal Ovules (also known as pessaries). This is a solid dosage form engineered to rapidly dissolve at body temperature, which then releases the medicine for targeted action upon insertion.

Q: Can men use Colpofilin for any reason?

The vaginal ovule formulation is specifically intended for female use, as reflected in the eligibility guidelines. Information regarding the treatment of sexual partners using the active ingredient's oral form is available separately.

Q: How does Colpofilin relate to the natural balance of the area it treats?

The product’s general purpose is to eliminate harmful populations of susceptible anaerobic bacteria and protozoa. This action is functionally aimed at correcting microbial imbalances and helping to restore the healthy state of the local environment.

Q: Is it possible to be allergic to Colpofilin?

The medicine is formally contraindicated in patients with a prior history of hypersensitivity or allergic reaction to metronidazole or other related compounds. Patients should discuss any history of such reactions with their healthcare provider.

Q: Are there any dietary restrictions mentioned for users of Colpofilin?

Official regulatory documents strictly restrict the consumption of alcohol (ethanol or products containing propylene glycol) during therapy and for at least three days after the final dose. This is due to the documented potential for a severe adverse reaction.

Q: Why is it listed as a treatment for conditions that are so different?

The active component has a distinct dual function, classified as both an Antiprotozoal agent and an Antibacterial agent. This wide range of activity allows it to target a variety of specific susceptible microorganisms, including both certain anaerobic bacteria and protozoa.

Q: Do studies suggest Colpofilin is effective for long-standing issues?

Research focuses on short-term efficacy and the initial clearance of the infection. The available long-term data are mainly limited to tracking the recurrence of the infection rather than drawing definitive conclusions about the management or sustained effectiveness for long-standing issues.

Q: Is the intended use of Colpofilin related to cell regeneration?

The official mechanism of action focuses on antimicrobial activity. This involves causing irreversible DNA damage and destruction to susceptible microorganisms, and it is not defined by promoting or involving cell regeneration.

Q: Can Colpofilin be used by individuals with chronic health conditions?

Regulatory documents advise caution and close medical oversight for use in patients with a history of severe hepatic disease or certain Central Nervous System (CNS) disorders. Individuals with chronic conditions should seek professional advice before use.

How to Store and Dispose of Colpofilin

All storage and handling instructions for Colpofilin (Metronidazole vaginal ovules) are defined by regulatory documents to maintain the product’s quality and stability.

Requirement Type	Official Labeled Condition
Temperature Range	Store at controlled room temperature, or below 30 C.
Environmental Control	Protect from light and store in a dry place, away from moisture and excess heat.
Handling Restriction	Do not freeze the ovules.
Packaging	Keep the medicine in its original package until the moment of use.
Child Safety	Must be kept strictly out of the sight and reach of children.

Disposal of Unused Product

Unused or expired Colpofilin must be disposed of according to local related guidelines for pharmaceutical waste. The official instruction is to prevent the product from entering wastewater and to utilize available drug take-back programs.